Back to Journals » International Journal of Women's Health » Volume 2

Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill

Authors Guida M, Bifulco G, di Spiezio Sardo A, Scala M, Fernandez LMS, Nappi C

Published 24 August 2010 Volume 2010:2 Pages 279—290


Review by Single anonymous peer review

Peer reviewer comments 3

Maurizio Guida, Giuseppe Bifulco, Attilio Di Spiezio Sardo, Mariamaddalena Scala, Loredana Maria Sosa Fernandez, Carmine Nappi
Dipartimento di Scienze Ostetriche Ginecologiche Urologiche e Medicina della Riproduzione Umana, Università degli Studi “Federico II”, Napoli, Italia

Abstract: The aim of this review is to define the role of the combined dienogest (DNG)/­estradiol valerate (E2V) contraceptive pill, in terms of biochemistry, metabolic and ­pharmacological effects and clinical application as well. E2V is the esterified form of 17β-estradiol (E2), while dienogest is a fourth-generation progestin with a partial antiandrogenic effect. The cycle stability is achieved with 2 to 3 mg DNG, supporting contraceptive efficacy. In this new oral contraceptive, E2V is combined with DNG in a four-phasic dose regimen (the first two tablets contain 3 mg E2V; the next five tablets include 2 mg E2V + 2 mg DNG, followed by 17 tablets with 2 mg E2V + 3 mg DNG; followed by two tablets with 1 mg E2V only, and finally two placebo tablets). Duration and intensity of scheduled withdrawal bleeding are lower with this ­contraceptive pill, whereas the incidence and the intensity of intra-cyclic bleeding are similar to the other oral contraceptive. With this new pill the levels of high density lipoprotein increased, while the levels of prothrombin fragment 1 + 2 and D-dimer remained relatively unchanged; the levels of sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin increased. The most frequently reported adverse events are: breast pain, headache, acne, alopecia, migraine, increase of ­bodyweight. The satisfaction rate is about 79.4%.

Keywords: estradiol valerate, dienogest, combined oral contraceptive, four-phasic regimen, contraceptive safety

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.